Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05609578 · ClinicalTrials.gov registry record · Phase 2

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

A Phase 2 study of Metastatic Lung Cancer and Advanced NSCLC, sponsored by Mirati Therapeutics.

Recruiting
Registry status
Phase 2
Development phase
90
Enrollment target
20
Study locations

NCT05609578: Recruiting Phase 2 study of Metastatic Lung Cancer and Advanced NSCLC, sponsored by Mirati Therapeutics.

NCT05609578 is a Phase 2 study of Metastatic Lung Cancer and Advanced NSCLC that is actively recruiting participants, run by Mirati Therapeutics. The registered enrollment target is 90 participants, below the 167-participant average among 10 other Metastatic Lung Cancer trials with a reported enrollment target (46% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05609578, a Phase 2 study of Metastatic Lung Cancer and Advanced NSCLC, is actively recruiting participants, sponsored by Mirati Therapeutics.

RECRUITING
Registry status
Phase 2
Development phase
90 participants
Enrollment target
20
Study locations

Study Summary

Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation

Primary Outcome

Defined as the percent of patients documented to have a confirmed CR or PR

Conditions Studied

Metastatic Lung Cancer Advanced NSCLC

Interventions

  • COMBINATION_PRODUCT Pembrolizumab
  • DRUG Adagrasib oral dose of 400 mg twice daily tablets
  • COMBINATION_PRODUCT Chemotherapy: Pemetrexed
  • COMBINATION_PRODUCT Cisplatin/Carboplatin

Study Locations (20)

Colorado

  • Local Institution - 017-872-I - Aurora
  • Local Institution - 017-872-G - Boulder
  • Local Institution - 017-872-D - Colorado Springs
  • Local Institution - 017-872-J - Colorado Springs
  • Local Institution - 017-872-B - Denver
  • Local Institution - 017-872-F - Denver
  • Local Institution - 017-872-A - Lakewood
  • Local Institution - 017-872-C - Littleton
  • USOR - Rocky Mountain Cancer Centers - Lone Tree - Sky Ridge Medical Center - Lone Tree
  • Local Institution - 017-872-E - Pueblo

California

  • Local Institution - Unk047 - Anaheim
  • Local Institution - 017-936C - Fountain Valley
  • MemorialCare - Orange Coast Medical Center - Fountain Valley
  • Providence Medical Foundation - Virginia K. Crosson Cancer Center - Fullerton - Fullerton
  • Local Institution - Unk004 - Loma Linda
  • Local Institution - 017-961 - Los Angeles
  • UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco

Arizona

  • Local Institution - 017-591 - Glendale
  • Local Institution - 017-821 - Phoenix

Alaska

  • Local Institution - Unk025 - Anchorage

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2022-11-22
Est. Completion 2026-12-01
Phase Phase 2
Mirati Therapeutics

49 total trials

What NCT05609578 shows while recruiting

NCT05609578 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 167-participant average among 10 other Metastatic Lung Cancer trials with a reported enrollment target (46% lower).

The record links to 2 conditions, with Metastatic Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT05609578 names 20 study sites across 4 states, led by Colorado, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT05609578 about?

NCT05609578 is a clinical study titled "Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation". Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation

What is the current status of trial NCT05609578?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2022-11-22. Estimated completion is 2026-12-01.

What conditions does trial NCT05609578 study?

This clinical trial studies the following conditions: Metastatic Lung Cancer, Advanced NSCLC.

What interventions are being tested in trial NCT05609578?

The interventions under investigation include: Pembrolizumab (COMBINATION_PRODUCT), Adagrasib oral dose of 400 mg twice daily tablets (DRUG), Chemotherapy: Pemetrexed (COMBINATION_PRODUCT), Cisplatin/Carboplatin (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT05609578?

This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05609578 being conducted?

This trial has 20 study locations across Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05609578's enrollment target sits among peer trials

90 6th of 10 higher than 5 of 10 other Metastatic Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05609578

Source: ClinicalTrials.gov NCT05609578, the US trial registry maintained by the National Library of Medicine. NCT05609578 (small enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.